R Griffiths1,2, D K Schlüter3, A Akbari1,2,4, R Cosgriff5, D Tucker6, D Taylor-Robinson3. 1. Swansea University Medical School, Swansea University. 2. Health Data Research UK. 3. Department of Public Health and Policy, University of Liverpool, Liverpool L69 7ZX. 4. Administrative Data Research Wales. 5. Cystic Fibrosis Trust, One Aldgate, London EC3N 1R. 6. Public Health Wales, Capital Quarter 2, Tyndall Street, Cardiff. CF10 4BZ\break † Joint First Authors.
Abstract
INTRODUCTION: The challenges in identifying a cohort of people with a rare condition can be addressed by routinely collected, population-scale electronic health record (EHR) data, which provide large volumes of data at a national level. This paper describes the challenges of accurately identifying a cohort of children with Cystic Fibrosis (CF) using EHR and their validation against the UK CF Registry. OBJECTIVES: To establish a proof of principle and provide insight into the merits of linked data in CF research; to identify the benefits of access to multiple data sources, in particular the UK CF Registry data, and to demonstrate the opportunity it represents as a resource for future CF research. METHODS: Three EHR data sources were used to identify children with CF born in Wales between 1st January 1998 and 31st August 2015 within the Secure Anonymised Information Linkage (SAIL) Databank. The UK CF Registry was later acquired by SAIL and linked to the EHR cohort to validate the cases and explore the reasons for misclassifications. RESULTS: We identified 352 children with CF in the three EHR data sources. This was greater than expected based on historical incidence rates in Wales. Subsequent validation using the UK CF Registry found that 257 (73%) of these were true cases. Approximately 98.7% (156/158) of individuals identified as CF cases in all three EHR data sources were confirmed as true cases; but this was only the case for 19.8% (20/101) of all those identified in just a single data source. CONCLUSION: Identifying health conditions in EHR data can be challenging, so data quality assurance and validation is important or the merit of the research is undermined. This retrospective review identifies some of the challenges in identifying CF cases and demonstrates the benefits of linking cases across multiple data sources to improve quality.
INTRODUCTION: The challenges in identifying a cohort of people with a rare condition can be addressed by routinely collected, population-scale electronic health record (EHR) data, which provide large volumes of data at a national level. This paper describes the challenges of accurately identifying a cohort of children with Cystic Fibrosis (CF) using EHR and their validation against the UK CF Registry. OBJECTIVES: To establish a proof of principle and provide insight into the merits of linked data in CF research; to identify the benefits of access to multiple data sources, in particular the UK CF Registry data, and to demonstrate the opportunity it represents as a resource for future CF research. METHODS: Three EHR data sources were used to identify children with CF born in Wales between 1st January 1998 and 31st August 2015 within the Secure Anonymised Information Linkage (SAIL) Databank. The UK CF Registry was later acquired by SAIL and linked to the EHR cohort to validate the cases and explore the reasons for misclassifications. RESULTS: We identified 352 children with CF in the three EHR data sources. This was greater than expected based on historical incidence rates in Wales. Subsequent validation using the UK CF Registry found that 257 (73%) of these were true cases. Approximately 98.7% (156/158) of individuals identified as CF cases in all three EHR data sources were confirmed as true cases; but this was only the case for 19.8% (20/101) of all those identified in just a single data source. CONCLUSION: Identifying health conditions in EHR data can be challenging, so data quality assurance and validation is important or the merit of the research is undermined. This retrospective review identifies some of the challenges in identifying CF cases and demonstrates the benefits of linking cases across multiple data sources to improve quality.
Authors: Rosy Tsopra; Daniel Peckham; Paul Beirne; Kirsty Rodger; Matthew Callister; Helen White; Jean-Philippe Jais; Dipansu Ghosh; Paul Whitaker; Ian J Clifton; Jeremy C Wyatt Journal: Int J Med Inform Date: 2018-03-27 Impact factor: 4.046
Authors: Rosy Tsopra; Jeremy C Wyatt; Paul Beirne; Kirsty Rodger; Matthew Callister; Dipansu Ghosh; Ian J Clifton; Paul Whitaker; Daniel Peckham Journal: J Eval Clin Pract Date: 2018-08-14 Impact factor: 2.431
Authors: David V Ford; Kerina H Jones; Jean-Philippe Verplancke; Ronan A Lyons; Gareth John; Ginevra Brown; Caroline J Brooks; Simon Thompson; Owen Bodger; Tony Couch; Ken Leake Journal: BMC Health Serv Res Date: 2009-09-04 Impact factor: 2.655
Authors: James H Boyd; Sean M Randall; Anna M Ferrante; Jacqueline K Bauer; Kevin McInneny; Adrian P Brown; Katrina Spilsbury; Margo Gillies; James B Semmens Journal: BMC Health Serv Res Date: 2015-08-08 Impact factor: 2.655
Authors: Kerina H Jones; David V Ford; Chris Jones; Rohan Dsilva; Simon Thompson; Caroline J Brooks; Martin L Heaven; Daniel S Thayer; Cynthia L McNerney; Ronan A Lyons Journal: J Biomed Inform Date: 2014-01-15 Impact factor: 6.317